Welcome to our dedicated page for Aflac SEC filings (Ticker: AFL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aflac Incorporated (NYSE: AFL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Fortune 500 insurer in the direct life and supplemental health insurance industry, Aflac uses its filings to report financial results, risk factors, capital structure changes and significant events affecting its U.S. and Japan operations.
Investors can review Aflac’s periodic reports, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, to understand segment performance for Aflac U.S. and Aflac Japan, trends in net earned premiums, adjusted earnings, investment income and capital position. These filings also discuss exposure to interest rate movements, foreign currency fluctuations in the yen/dollar exchange rate, regulatory developments and other risks that the company identifies as material to its business.
Current reports on Form 8-K offer more timely updates on specific events. Recent 8-K filings have covered quarterly financial results, supplemental earnings materials, investor presentations and a cybersecurity incident involving unauthorized access to Aflac’s network. Other 8-Ks describe financing arrangements, including contingent funding facilities and pre-capitalized trust securities that give Aflac the right to issue senior notes under defined conditions.
On Stock Titan, these filings are supplemented with AI-powered summaries that explain key points in clear language, helping users interpret complex sections on financial condition, liquidity, capital management and risk disclosures. The platform also surfaces relevant forms such as Form 4 insider transaction reports, proxy materials on executive and director matters, and other documents that can be important for evaluating governance and insider activity.
By using this page, readers can track Aflac’s real-time filing activity from EDGAR, quickly grasp the implications of lengthy documents through AI-generated highlights, and reference the underlying full-text filings for deeper analysis of AFL’s regulatory and financial reporting history.
AFL filed a Form 144 notice for a proposed sale under Rule 144. The seller plans to sell 1,722 shares of common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $193,725 and an approximate sale date of 11/06/2025.
The shares come from restricted stock vesting awards: 852 shares on 09/15/2024 and 870 shares on 09/15/2025, received as compensation. Shares outstanding were 524,113,917.
Aflac Incorporated filed an 8-K announcing its 2025 third quarter results. The company furnished a press release and supplemental earnings materials as Exhibits 99.1 and 99.2 dated November 4, 2025.
Under Regulation FD, Aflac also posted a video presentation by Senior Executive Vice President and CFO Max Brodén on investors.aflac.com, with the transcript and slides furnished as Exhibits 99.3 and 99.4.
Max K. Broden, Sr. EVP and CFO of Aflac Incorporated (AFL), filed a Form 4 reporting insider transactions dated 09/23/2025. The filing lists a transaction coded F disposing of 33 shares at a price of $108.23. The form shows 339 shares beneficially owned following the reported transaction(s). The filing also includes an entry showing Common Stock 130,353 D (disposition) on the form. The Form 4 was signed for Max K. Broden by Cathryn S. Smitherman on 09/25/2025.
Frederic Simard, listed as EVP, COO & CFO, Aflac U.S., reported a sale of 493 shares of AFL common stock on 09/15/2025 at a price of $108.41 per share. After the sale he beneficially owns 3,086 shares directly and holds 589 shares indirectly through a 401(k) plan. The Form 4 was signed on 09/17/2025.
Aflac Incorporated entered into two contingent funding arrangements through Wynnton Funding Trusts that issued $1,000,000,000 of 2035 P-Caps and $1,000,000,000 of 2055 P-Caps to institutional investors. In return, Aflac pays a 0.9875% facility fee per annum on an unexercised right to issue up to $1,000,000,000 of 5.251% Senior Notes due 2035 and a 1.1218% facility fee per annum on an unexercised right to issue up to $1,000,000,000 of 5.991% Senior Notes due 2055. These Issuance Rights can be exercised voluntarily or automatically upon events such as missed facility fee payments, certain bankruptcy events, or if Aflac’s consolidated net worth (excluding accumulated other comprehensive income and certain non-controlling interests) falls below $10 billion, giving the company pre-arranged access to long-dated senior funding.
Joseph L. Moskowitz, a director of Aflac Inc. (AFL), reported a change in beneficial ownership on 08/18/2025. The filing shows 500 shares disposed (D) of Aflac common stock under transaction code G at a recorded price of $0, leaving 24,605 shares beneficially owned directly after the transaction. The Form 4 was signed on 08/20/2025.
Bradley E. Dyslin, Executive Vice President of Aflac Incorporated, received a grant of 9,658 shares of Aflac common stock under the companys Long-Term Incentive Plan. The award was recorded as an acquisition and is listed at a price of $0, indicating a grant rather than a market purchase. Following this transaction, Mr. Dyslins reported beneficial ownership of Aflac common stock is 29,162 shares, held directly.
The Form 4 discloses the transaction class as common stock and cites the Long-Term Incentive Plan (as amended and restated February 14, 2017) as the grant source. The filing identifies Mr. Dyslin as an officer (Executive Vice President) of the issuer.
Joseph L. Moskowitz, identified as a Director of Aflac Inc., reported the sale of 1,000 shares of Aflac common stock on 08/08/2025 at a price of $102.57 per share. After the reported transaction the filing shows he beneficially owned 25,105 shares. The Form 4 indicates it was filed by one reporting person and bears a signature date of 08/12/2025.
The filing states the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 4, 2024. No derivative transactions are reported in the document, and the form includes the reporting person's address and role. The disclosure is limited to the transactions described and the plan referenced.
FAQ
What is the current stock price of Aflac (AFL)?
What is the market cap of Aflac (AFL)?
